Biotest Balance Sheet Health
Financial Health criteria checks 3/6
Biotest has a total shareholder equity of €498.9M and total debt of €632.0M, which brings its debt-to-equity ratio to 126.7%. Its total assets and total liabilities are €1.4B and €912.0M respectively. Biotest's EBIT is €116.7M making its interest coverage ratio 3.4. It has cash and short-term investments of €118.5M.
Key information
126.7%
Debt to equity ratio
€632.00m
Debt
Interest coverage ratio | 3.4x |
Cash | €118.50m |
Equity | €498.90m |
Total liabilities | €912.00m |
Total assets | €1.41b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BIO3's short term assets (€756.5M) exceed its short term liabilities (€385.3M).
Long Term Liabilities: BIO3's short term assets (€756.5M) exceed its long term liabilities (€526.7M).
Debt to Equity History and Analysis
Debt Level: BIO3's net debt to equity ratio (102.9%) is considered high.
Reducing Debt: BIO3's debt to equity ratio has increased from 65.9% to 126.7% over the past 5 years.
Debt Coverage: BIO3's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: BIO3's interest payments on its debt are well covered by EBIT (3.4x coverage).